ALK, ROS1, TrkA, TrkB, TrkC

ALK, ROS1, TrkA, TrkB, and TrkC are all receptor tyrosine kinases considered therapeutic targets in oncology, particularly for cancers driven by gene fusions or aberrant activation. These targets represent distinct proteins from two main families: - Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in nervous system development and is frequently altered in cancers by gene fusions, mutations, or overexpression. - Proto-oncogene tyrosine-protein kinase ROS1 (ROS1) is another receptor tyrosine kinase with roles in cell differentiation and proliferation; it is implicated in several cancers via gene rearrangements. - TrkA, TrkB, and TrkC are members of the tropomyosin receptor kinase (TRK) family, encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. They bind specific neurotrophins, triggering cell survival, differentiation, and proliferation signals. ALK, ROS1, TrkA, TrkB, and TrkC are receptor tyrosine kinases serving critical roles in signal transduction pathways that govern cell survival, proliferation, and neuronal differentiation. Aberrant activation through genetic fusions or mutations is implicated in various cancers, making these proteins prime therapeutic targets for small molecule kinase inhibitors. Clinically validated drugs target these kinases in multiple solid tumors, and ongoing research continues to address resistance and safety challenges.

Other names

Anaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS1Tropomyosin receptor kinase ATropomyosin receptor kinase BTropomyosin receptor kinase CNTRK1NTRK2NTRK3

Small molecule inhibitors block kinase activity, preventing autophosphorylation and stopping downstream signaling pathways associated with cell proliferation and survival.